Estimation of probability of malignancy using a logistic model combining physical examination, ultrasound, serum CA 125, and serum CA 72-4 in postmenopausal women with a pelvic mass: An international multicenter study

Gynecologic Oncology

Volumn 69, Issue 1, 1998, Pages 56-63

  Schutter, E M J ^a   Sohn, C ^b   Kristen, P ^c   Mobus V ^e   Crombach, G ^d   Kaufmann, M ^b   Caffier, H ^c   Kreienberg, R ^e   Verstraeten, A A ^a   Kenemans, P ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^c UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^d UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^e UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

Author keywords

CA 125; CA 72 4; Differential diagnosis; Ovarian cancer; Pelvic mass; Physical examination; Ultrasonogtaphy

Indexed keywords

CA 125 ANTIGEN; CA 72-4 ANTIGEN;

ADULT; AGED; ARTICLE; BENIGN TUMOR; CLINICAL TRIAL; DIAGNOSTIC ACCURACY; DIFFERENTIAL DIAGNOSIS; ECHOGRAPHY; FEMALE; HISTOPATHOLOGY; HUMAN; IMMUNORADIOMETRIC ASSAY; MAJOR CLINICAL STUDY; MALIGNANT NEOPLASTIC DISEASE; MULTICENTER STUDY; OVARY CANCER; PELVIS TUMOR; PHYSICAL EXAMINATION; POSTMENOPAUSE; PREDICTION; PRIORITY JOURNAL; SCORING SYSTEM; STATISTICAL MODEL;

EID: 0032054123     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1006/gyno.1998.4942     Document Type: Article

References (69)

1. Schutter E MJ, Kenemans P, Sohn C, Kristen P, Crombach G, Westermann R, Möbus V, Kaufmann M, Caffier H, Schmidt-Rhode P, Kreienberg R, Verstraeten A A, Cornillie F. Diagnostic value of pelvic examination, ultrasound and serum CA 125 in postmenopausal women presenting with a pelvic mass, an international multicenter study. Cancer. 74:1994;1398-1406.
2. Berek J, Hacker N. Practical Gynecologic Oncology. 1989;Williams and Wilkins, Baltimore. p. 328.
3. Nutti M, Teramoto Y A, Mariani-Costanti R, Horan Hand P, Colcher D, Schlom J. A monoclonal antibody (B 72.3) defines patterns of distribution of a novel tumor-associated antigen in human mammary cell polupaltions. Int J Cancer. 29:1982;539-545.
4. Thor A, Ohuchi N, Szpak C A, Johnston W W, Schlom J. Distribution of oncofetal antigen tumor-associated glycoprotein-72 defined by monoclonal antibody B72.3. Cancer Res. 46:1986;3118-3124.
5. Paterson A J, Schlom J, Sears H F. A radioimmunoassay for the detection of a human tumor-associated glycoprotein (TAG-72) using monoclonal antibody B 72.3. Int J Cancer. 37:1986;659-666.
6. Einhorn N, Knapp R C, Bast R C Jr, Zurawski V R. CA 125 assay used on conjunction with CA 15-3 and TAG-72 assays for discriminating malignant and non-malignant diseases of the ovary. Acta Oncol. 28:1989;655-657.
7. Soper J T, Hunter U J, Daly L, Tanner M, Creasman W T, Bast R C Jr. Preoperative serum tumor-associated antigen levels in women with pelvic masses. Obstet Gynecol. 75:1990;249-254.
8. Ferroni P, Szpak C, Greiner J W, Simpson J F, Guadagni F, Johnston W W, Colcher D. CA 72-4 radioimmunoassay in the diagnosis of malignant effusions. Comparison of various tumor markers. Int J Cancer. 46:1990;445-451.
9. Bast R C Jr, Knauf S, Epenetos A, Dhokia B, Daly L, Tanner M, Soper J, Creasman W, Gall S, Knapp R C, Zurawski V R, Schlom J, Kufe D W, Ritts R E Jr. Coordinate elevation of serum markers in ovarian cancer but not in benign disease. Cancer. 68:1991;1758-1763.
10. Wu J T, Carlisle P. Low frequency and low level of elevation of serum CA 72-4 in human carcinomas in comparison with established tumor markers. J Clin Lab Anal. 6:1992;59-64.
11. Gaducci A, Ferdeghini M, Prontera C, Moretti L, Mariani G, Bianchi R, Fioretti P. The concomitant determination of different tumor markers in patients with epithelial ovarian cancer and benign ovarian masses: relevance for differential diagnosis. Gynecol Oncol. 44:1992;147-154.
12. Fioretti P, Gaducci A, Ferdeghini M, Prontera C, Malagnino G, Facchini V, Bianchi R. The concomitant determination of different serum tumor markers in epithelial ovarian cancer: relevance for monitoring the response to chemotherapy and follow-up of patients. Gynecol Oncol. 44:1992;155-169.
13. Gadducci A, Capriello P, Ferdeghini M, Madrigali A, Puccetti A, Annicchiarico C, Prontera C, Bianchi R, Fioretti P. Pelvic ultrasound, serum CA 125 assay, CA 19.9 assay and serum CA 72.4 assay in the differential diagnosis of ovarian masses. Cancer J. 4:1991;249-253.
14. Guadagni F, Roselli M, Amato T, Cosimelli M, Manella E, Perri P, Abbolito M R, Cavaliere R, Colcher D, Greiner J W, Schlom J. Tumor-associated glycoprotein-72 (TAG-72) serum levels complement carcinoembryonic antigen (CEA) levels in monitoring patients with gastrointestinal carcinoma: a longitudinal study. Cancer. 68:1991;2443-2450.
15. Guadagni F, Roselli M, Amato T, Cosimelli M, Perri P, Casale V, Carlini M, Santoro E, Cavaliere R, Greiner J W, Schlom J. CA 72-4 measurement of tumor-associated glycoprotein 72 (TAG-72) as a serum marker in the management of gastric carcinoma. Cancer Res. 52:1992;1222-1227.
16. Guadagni F, Marth C, Zeimet A G, Ferroni P, Amato T, Abbolito R, Roselli M, Greiner J W, Schlom J. Evaluation of CA 72-4 and CA 125 serum markers in patients with gynecological diseases. Am J Obstet Gynecol. 11:1994;1183-1191.
17. Gero E J, Colcher D, Ferroni P, Melsheimer R, Giani S, Schlom J, Kaplan P. The CA 72-4 radioimmunoassay for the detection of the TAG-72 carcinoma associated antigen in serum of patients. J Clin Lab Anal. 3:1989;360-369.
18. Joypaul B, Browning M, Newman E, Byrne D, Cuschieri A. Comparison of serum CA 72-4 and CA 19-9 levels in gastric cancer patients and correlation with recurrence. Am J Surg. 169:1995;595-599.
19. Maggino T, Gadducci A, D'Addrio V, Pecorelli S, Lissoni A, Stella M, Romagnolo C, Ferdeghini M, Zucca S, Trio D, Trovó S. Prospective multicenter study on the clinical utility of CA 72.4 in postmenopausal patients with pelvic mass. Oncol Rep. 2:1995;1069-1074.
20. Reiter W, Stieber P, Reuter C, Nagel D, Cramer C, Fateh-Moghadam A. Sensitivity and prognostic significance of CA 72-4, CEA, and CA 19-9 serum levels in untreated patients with gastric cancer. Tumordiagn Ther. 16:1995;98-101.
21. Sperti C, Pasquali C, Guolo P, Polverosi R, Liessi G, Pedrazzoli S. Serum tumor markers and cyst fluid analysis are useful for the diagnosis of pancreatic cystic tumors. Cancer. 78:1996;237-243.
22. Lindmark G, Kressner U, Bergström R, Glimelius B. Limited clinical significance of the serum tumour marker CA 72-4 in colorectal cancer. Anticancer Res. 16:1996;895-898.
23. Spila A, Roselli M, Cosimelli M, Ferroni P, Cavaliere F, Arcuri R, Tedesco M, Carlini S, D'Alessandro R, Perri P, Casciani C U, Greiner J W, Schlom J, Guadagni F. Clinical utility of CA 72-4 serum marker in the staging and immediate post-surgical management of gastric cancer patients. Anticancer Res. 16:1996;2241-2248.
24. Hasholzner U, Baumgartner L, Stieber P, Meier W, Reiter W, Pahl H, Fateh-Moghadam A. Clinical significance of the tumour markers CA 125 II and CA 72-4 in ovarian carcinoma. Int J Cancer (Pred Oncol). 69:1996;329-334.
25. Finkler N J, Benacerraf B, Lavin P T, Wojciechowski C, Knapp R C. Comparison of serum CA 125, clinical impression, and ultrasound in the preoperative evaluation of ovarian masses. Obstet Gynecol. 72:1988;659-664.
26. Rulin M C, Preston A L. Adnexal masses in postmenopausal women. Obstet Gynecol. 70:1987;578-581.
27. Meire H B, Farrant P, Guha T. Distinction of benign from malignant ovarian cysts by ultrasound. Br J Obstet Gynaecol. 85:1978;893-899.
28. Hermann U J Jr, Locher G W, Goldhirsch A. Sonographic Patterns of ovarian tumors: prediction of malignancy. Obstet Gynecol. 69:1987;777-781.
29. Andolf E, Jörgensen C, Åstedt B. Ultrasound examination for detection of ovarian carcinoma in risk groups. Obstet Gynecol. 106:1990;106-109.
30. Andolf E, Jörgensen C. A prospective comparison of clinical ultrasound and operative examination of the female pelvis. J Ultrasound Med. 7:1988;617-620.
31. Andolf E, Jörgensen C. Simple adnexal cysts diagnosed by ultrasound in postmenopausal women. J Clin Ultrasound. 16:1988;301-303.
32. Benacerraf B R, Finkler N, Wojciechowski C, Knapp R C. Sonographic accuracy in the diagnosis of ovarian masses. J Reprod Med. 35:1990;491-495.
33. Tay S K, Tan Y Y. Risk factors and a risk scoring system for the prediction of malignancy in ovarian cysts. Austr NZ J Obstet Gynaecol. 32:1992;341-345.
34. Bast R, Klug T, St John E, Jenison E, Niloff J, Lazarus H, Berkowitz R, Leavitt T, Griffiths T, Parker L, Zurawki V, Knapp R. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med. 309:1983;883-887.
35. Klug T, Bast R, Niloff J, Knapp R, Zurawski V. A monoclonal antibody immunoradiometric assay for an antigenic determinant (CA 125) associated with human epithelial ovarian carcinomas. Cancer Res. 44:1984;1048-1053.
36. Kenemans P, Yedema C A, Bon G G, von Mensdorff-Pouilly S. CA 125 in gynecological pathology-a review. Eur J Obstet Gynecol Reprod Biol. 49:1993;115-124.
37. Jacobs L, Bast R. The CA 125 tumor-associated antigen: a review of the literature. Hum Reprod. 4:1989;1-12.
38. Einhorn N, Bast R C, Knapp R C, Tjenberg B, Zurawski V. Preoperative evaluation of serum CA 125 levels in patients with primary epithelial ovarian cancer. Obstet Gynecol. 67:1986;414.
39. O'Connell G, Ryan E, Murphy J, Prefontaine M. Predictive value of CA 125 for ovarian carcinoma in patients presenting with pelvic masses. Obstet Gynecol. 70:1987;930-932.
40. Swets J A. Measuring the accuracy of diagnostic systems. Science. 240:1988;1285-1293.
41. van Kamp G J, Bon G G, Verstraeten R A, Lynch D, Krikau M, Flückiger J, Ruibal A, Kenemans P. Multicenter evaluation of the Abbott IMx CA 15-3 assay. Clin Chem. 42:1996;28-33.
42. Gardner M J, Altman D G. Confidence intervals rather than P values: estimation rather than hypothesis testing. Br Med J. 292:1986;746-750.
43. Diamond G A. Limited assurances. Am J Cardiol. 63:1989;99-100.
44. Buist M R, Golding R P, Burger C W, Vermorken J B, Kenemans P, Schutter E MJ, Baak J PA, Heitbrink M A, Falke T HM. Comparative evaluation of diagnostic methods in ovarian carcinoma with emphasis on CT and MRI. Gynecol Oncol. 52:1994;191-198.
45. Sassone M, Timor-Tritsch I, Artner A, Westhoff C, Warren W. Transvaginal sonographic characterization of ovarian disease: evaluation of a new scoring system to predict ovarian malignancy. Obstet Gynecol. 78:1991;70-76.
46. Granberg S, Norström A, Wikland M. Tumors in the lower pelvis as imaged by vaginal sonography. Gynecol Oncol. 37:1990;224-229.
47. Bourne T, Campbell S, Steer C, Whitehead M I, Collins W P. Transvaginal color flow imaging: a possible new screening technique for ovarian cancer. Br Med J. 299:1989;1367-1370.
48. Kawai M, Kano T, Kikkawa F, Maeda O, Oguchi H, Tomoda Y. Transvaginal doppler ultrasound with color flow imaging in the diagnosis of ovarian cancer. Obstet Gynecol. 79:1992;163-167.
49. Weiner Z, Thaler I, Beck D, Rottem S, Deutsch M, Brandes J. Differentiating malignant from benign ovarian tumors with transvaginal color flow imaging. Obstet Gynecol. 79:1992;159-162.
50. Schneider V L, Schneider A, Reed K, Hatch K D. Comparison of Doppler with two-dimensional sonography and CA 125 for prediction of malignancy of pelvic masses. Obstet Gynecol. 81:1993;983-988.
51. Vasilev S A, Schlaerth J B, Campeau J, Morrow C P. Serum CA 125 levels in preoperative evaluation of pelvic masses. Obstet Gynecol. 71:1988;751-756.
52. Di-Xia C, Schwartz P, Zinguo L, Zhan Y. Evaluation of CA 125 levels in differentiating malignant from benign tumors in patients with pelvic masses. Obstet Gynecol. 72:1988;23-27.
53. Yedema C, Massuger L, Hilgers J, Servaas J, Poels L, Thomas C, Kenemans P. Pre-operative discrimination between benign and malignant ovarian tumors using a combination of CA 125 and CA 15.3 serum assays. Int J Cancer (Suppl). 3:1988;61-67.
54. Mastropaolo W, Fernandez Z, Miller E L. Pronounced increase in the concentration of an ovarian tumor marker, CA 125, in serum of a healthy subject during menstruation. Clin Chem. 32:1986;2110-2111.
55. Malkasian G D Jr, Knapp R C, Lavin P T, Zurawski V R, Podratz K C, Stanhope C R, Mortel R, Berek J S, Bast R C, Ritts R E. Preoperative evaluation of serum CA 125 levels in premenopausal and postmenopausal patients with pelvic masses: Discrimination of benign from malignant disease. Am J Obstet Gynecol. 159:1988;341-346.
56. Zurawski V, Knapp R, Einhorn N, Kenemans P, Mortel R, Ohmi K, Bast R, Malkasian G. An initial analysis of preoperative serum CA 125 in patients with early stage ovarian carcinoma. Gynecol Oncol. 30:1988;7-14.
57. Inoue M, Fukita M, Nakazawa A, Ogawa H, Tanizawa O. Sialyl-Tn, Sialayl-Lewis XI, CA 19.9, CA 125, Carcinoembryonic antigen, and tissue polypeptide antigen in differentiating ovarian cancer from benign tumors. Obstet Gynecol. 79:1992;434-440.
58. Woolas R P, Conaway M R, Xu F, Jacobs I J, Yu Y, Daly L, Davies A P, O'Briant K, Berchuck A, Soper J T, Clarke-Pearson D L, Rodriguez G, Oram D H, Bast R C Jr. Combinations of multiple serum markers are superior to individual assays for discriminating malignant from benign pelvic masses. Gynecol Oncol. 59:1995;111-116.
59. Wolf R C, D'Emilia J C, Salem R R, DeCoste D, Sears H F, Gottlieb L S, Steele G D Jr. Detection of tumor-associated glycoprotein antigen (TAG-72) in premalignant lesions of the colon. J Natl Cancer Inst. 81:1989;1913-1917.
60. Thor A, Viglione M J, Muraro R, Ohuchi N, Schlom J, Gorstein F. Monoclonal antibody B72.3 reactivity with human endometrium: a study of normal and malignant tissues. Int J Gynecol Pathol. 6:1987;235-247.
61. Lopez L A, Del Villar V, Ulla M, Fernandez F, Fernandez L A, Santos I, Rabadan L, Gutierrez M. Prevalence of abnormal levels of serum tumour markers in elderly people. Age Ageing. 25:1996;45-50.
62. Jacobs I J, Oram D, Bast R C Jr. Strategies for improving the specificity of screening for ovarian cancer with tumor-associated antigens CA 125, CA 15-3, and TAG 72.3. Obstet Gynecol. 80:1992;396-399.
63. Lahousen M, Stettner H, Pickel H, Urdl W, Pürstner P. The predictive value of a combination of tumor makers in monitoring patients with ovarian cancer. Cancer. 60:1987;2228-2232.
64. Panza N, Pacilio G, Campanella L, Peluso G, Battista C, Amoriello A, Utecht W, Vacca C, Lombardi G. Cancer antigen 125, tissue polypeptide antigen, carcinoembryonic antigen, and beta-chain human chorionic gonadotropin as serum markers of epithelial ovarian carcinoma. Cancer. 61:1988;76-83.
65. Vardi J R, Tadros G H, Foemmel R, Shebes M. Plasma lipid-associated sialic acid and serum CA 125 as indicators of disease status with advanced ovarian cancer. Obstet Gynecol. 74:1989;379-383.
66. Tholander B, Taube A, Lindgren A, Sjöberg O, Stendahl U, Kiviranta A, Hallman K, Holm L, Weiner E, Tamsen L. Pretreatment serum levels of CA 125, Carcinoembryonic antigen, tissue polypeptide antigen, and placental alkaline phosphatase, in patients with ovarian carcinoma, borderline tumors, or benign adnexal masses: relevance for differential diagnosis. Gynecol Oncol. 39:1990;16-25.
67. Toftager-Larsen K, Hörding U, Dreisler A, Daugaard S, Lund B, Bock J, Lindvall F, Frederiksen K, Nörgaard-Pedersen B. CA 125, placental alkaline phosphatase and tissue polypeptide antigen as preoperative serum marker in ovarian carcinoma. Gynecol Obstet Invest. 33:1992;177-182.
68. Nezhat F, Nezhat C, Welander C E, Benigno B. Four ovarian cancers diagnosed during laparoscopic management of 1011 women with adnexal masses. Am J Obstet Gynecol. 167:1992;790-796.
69. Maiman M, Seltzer V, Boyce J. Laparoscopic excision of ovarian neoplasms subsequently found to be malignant. Obstet Gynecol. 77:1991;563-565.